BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

European Patent Office to Grant Patent for Macrocure's CureXcell®


3/14/2013 10:03:22 AM

PETACH TIKVA, Israel, March 14, 2013 -- /PRNewswire/ --Macrocure (http://www.macrocure.com), a biotechnology company developing advanced cell therapy products, announced today that the European Patent Office (EPO) intends to grant a European patent covering Marcocure's flagship product, CureXcell®. The patent will be officially granted under an application titled "Activate Leukocyte Composition" and will provide patent coverage for CureXcell® in Europe through March 2030.

CureXcell® is a novel approach to treating hard-to-heal wounds by replenishing the imbalanced inflammatory environment in non-healing wounds with a broad array of functionally-active allogeneic immune cells. These cells are superficially injected into the wound bed, once a month, and release the necessary cytokines and growth factors for the wound to heal.

About 5,000 patients with various types and severities of hard-to-heal wounds have been treated in Israel. CureXcell® has been approved for reimbursement by the Israeli Ministry of Health.

"The granting of a European patent for CureXcell® is a significant milestone for MacroCure, which fits with our strategy to become a leader in the hard to heal wound treatment market in Europe," said Nissim Mashiach, President and CEO of Macrocure.

About Macrocure

Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies. Macrocure is pursuing regulatory market approval in North America and Europe. CureXcell® is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with diabetes under SPA in the United States, Canada and Israel. The product has marketing authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States or Canada.

Media Contact:

Matthew Krieger Finn Partners Israel for Macrocure +972-544-676-950 matthew@finnpartners.co.il

SOURCE Macrocure



Read at BioSpace.com

Macrocure
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES